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S2The patient with thoracic aortic aneurysm disease requires careful evaluation and management over his or
her lifetime. This includes assessment for the presence of an underlying genetic disorder, such as Marfan
syndrome, bicuspid aortic valve disease, or a familial aortic aneurysm syndrome. Screening family mem-
bers is necessary, inasmuch as up to 20% of first-degree relatives of the patient with a thoracic aortic an-
eurysm will also have aneurysm disease. Medical therapy is often prescribed, and beta-blocker therapy to
reduce the stress on the aortic wall is usually recommended. However, very few clinical trials of pharma-
cologic therapy in humans with thoracic aortic aneurysm disease have been conducted. Mouse models have
led to important discoveries and insight into the pathogenesis of aneurysm syndromes, and there is hope
these may lead to effective therapy in people. Several studies are ongoing that examine the role of angio-
tensin receptor blockers in Marfan syndrome. Lifestyle modification is also important for patients with tho-
racic aortic aneurysm, including restrictions on physical activity, weight lifting, and recommendations about
the management of pregnancy. Long-term surveillance of the aorta, even after successful surgery, is neces-
sary for timing of prophylactic surgery and to evaluate for late complications. (J Thorac Cardiovasc Surg
2013;145:S2-6)Thoracic aortic aneurysm (TAA) is due to multiple disor-
ders (Table 1) and has an estimated incidence of approxi-
mately 10 per 100,000 person-years.1 The natural history
and treatment strategy depend on the location of the
aneurysm and its underlying cause.1 Although aneurysms
reaching a certain size are generally treated with surgery
or endovascular therapy, many aspects of medical manage-
ment of TAA disease are worth emphasizing.
First, when evaluating the patient with TAA disease, it
is essential to make a correct diagnosis of the underlying
condition. Genetically triggered diseases may have over-
lapping phenotypes, and accurate diagnosis is important
for surgical decision making and for identifying affected
relatives.1,2 Much of the data regarding pharmacologic
therapy for TAA disease is derived from mouse model
studies, such as fibrillin-1–deficient (Marfan) mice.
There are few studies on the pharmacologic treatment
of TAA disease in humans. Lifestyle modification (such
as that related to exercise, pregnancy, and work) is
essential in the management of patients with TAA
disease. Finally, long-term surveillance of the aorta is re-
quired before and after surgery for patients with TAA
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The Journal of Thoracic and Cardiovascular SurgeDIAGNOSIS OF UNDERLYING DISEASE
When the individual with TAA disease is being evalu-
ated, there may be clues from the history, family history,
and physical examination that assist in the diagnosis of
the correct underlying disease.2,3 Not only is it important
to evaluate the subject with TAA for these findings, but it
is also helpful to inquire as to whether any family
members have features of an underlying connective tissue
disease or aortopathy. In some instances, an affected
family member will have more striking features of the
underlying disease, and this will assist with the correct
diagnosis. A family history of TAA, bicuspid aortic valve
(BAV), cerebral aneurysm, aortic dissection, or features of
an underlying connective tissue disorder should be queried.
Marfan syndrome is due to mutations in the FBN1 gene
and leads to multisystem findings including skeletal fea-
tures (tall stature, scoliosis, pectus deformities, elongated
fingers and toes, hyperflexibility), ocular involvement
(lens dislocation, high myopia), and cardiovascular disease
(aortic root aneurysm, aortic dissection, mitral valve pro-
lapse).2 Loeys-Dietz syndrome is due to mutations in
TGFBR1 and TGFBR2 genes and has a characteristic triad
of craniofacial features (craniosynostosis, bifid uvula,
hypertelorism), aortic root and branch vessel aneurysm
and dissection, and arterial tortuosity.4 BAVaffects approx-
imately 1% of the population and may be familial in
approximately 9% of cases.5 Many patients with BAV
disease have associated ascending aortic aneurysm, and
BAVaortopathy may be familial.5 Familial TAA syndromes
are being more commonly recognized.3 ACTA2 gene muta-
tions affect approximately 14% of individuals with familial
TAA disease and are associated with livedo reticularis, iris
flocculi, cerebral aneurysms, premature coronary and cere-
brovascular disease, moyamoya, and patent ductusry c March 2013
Braverman Panel 1Abbreviations and Acronyms
AAA ¼ abdominal aortic aneurysm
ACE ¼ angiotensin converting enzyme
ARB ¼ angiotensin receptor blocker
AT1 ¼ angiotensin II type 1
AT2 ¼ angiotensin II type 2
BAV ¼ bicuspid aortic valve
TAA ¼ thoracic aortic aneurysm
TGF-b ¼ transforming growth factor-barteriosus.1,3 Because of the overlap in phenotype, in many
instances where there is ambiguity in diagnosis, mutation
analysis may be necessary for correct diagnosis and for
the evaluation of relatives.2,3 Importantly, up to 20% of
patients with a TAA will have another first-degree relative
with thoracic aortic disease.1,3
Imaging studies may provide clues as to the underlying
disorder leading to TAA. The pattern of aortic dilatation
may be informative. Marfan syndrome and Loeys-Dietz
syndrome lead to aneurysms of the aortic root and si-
nuses of Valsalva.2 BAV aortopathy may involve the aor-
tic root but more commonly leads to aneurysm located in
the mid–ascending aorta.5 Additionally, the presence of
lumbosacral dural ectasia discovered in the aneurysm
patient should trigger the evaluation of an underlying
disease such as Marfan syndrome or Loeys-Dietz
syndrome.2
PHARMACOLOGIC THERAPY
Medical management of the patient with TAA disease in-
volves treatment of hypertension, optimal lipid control, and
smoking cessation.3 Although the pathophysiology differs
for the various causes of TAA (Table 1), basic treatment
strategies may apply. These include medications to lessen
blood pressure and reduce aortic wall stress and guidelines
to modify lifestyle—such as physical activity, weight-
lifting restrictions, and pregnancy recommendations.3
Beta-blockers, owing to their effects on reducing the
inotropic state of the heart, decreasing the impact force of
ejected blood on the aorta, and lowering heart rate and
blood pressure, have been a mainstay in the treatment of-
TAA.3 Nonrandomized clinical trials suggested beta-
blocker use was associated with decreased abdominal aortic
aneurysm (AAA) enlargement, although 2 randomized
trials did not demonstrate a reduction in AAA growth rate
with propranolol.6,7
In 1971, Halpern theorized that beta-blocker therapy may
reduce aortic dissection in patients with Marfan syndrome.8
There are several lines of evidence to support this proposal.
In patients with malignant hypertension, reducing bloodThe Journal of Thoracic and Capressure to normal—but failing to reduce the rate of rise of
blood pressure—did not reduce risk of dissection.6,8 Also,
the contractile strength of the myocardium and the strength
of pulsation are important in progression of aortic
dissection.6,7 In early studies of hypertensive patients, beta-
blockers were effective in the management of aortic dissec-
tion.6-8 Additionally, research demonstrated that turkeys
prone to spontaneous aortic dissection or rupture had
improved survivalwhenpropranololwas added to their feed.6,8
There have been several studies of beta-blockers in
Marfan syndrome examining short- or long-term effects
on the biomechanical properties of the aorta, both inva-
sively and noninvasively, with mixed results.6,7,9 In
a 10-year study of beta-blockers in Marfan syndrome,
those treated with propranolol had a lower rate of aortic
root dilatation than untreated patients.8 A retrospective
nonrandomized study of beta-blocker use in children
with Marfan syndrome also demonstrated a slowing of
aortic dilatation in patients treated with beta-blockers
compared with untreated controls.10 The recently pub-
lished thoracic aortic disease guidelines have recommen-
ded beta-blocker therapy be administered to patients with
Marfan syndrome and aortic aneurysm to reduce the rate
of aortic dilatation.3
With the discovery of FBN1 mutations leading to abnor-
malities in fibrillin-1 as the underlying defect in Marfan
syndrome, the basic pathophysiology of this disease is
being elucidated using mouse models.11 In addition to di-
recting elastic tissue formation and providing structural in-
tegrity to tissues, fibrillin-1 interacts with latent
transforming growth factor-b (TGF-b)–binding proteins
and controls TGF-b activation and signaling.11 Deficiency
of fibrillin-1 microfibrils results in excessive TGF-b activa-
tion and signaling in tissues altered by Marfan syndrome.11
Angiotensin is also important in TGF-b signaling, and
blocking TGB-b, using neutralizing antibody or the angio-
tensin II type 1 (AT1) receptor blocker (ARB) losartan, can
prevent or attenuate aneurysm formation in Marfan mice.11
ARB therapy has been demonstrated to reduce plasma
levels of free TGF-b, reduce tissue expression of TGF-b–re-
sponsive genes, and reduce levels of intracellular mediators
within the TGF-b signaling cascade.12 Thrombospondin-1
and matrix metalloproteinase levels are also reduced with
ARB therapy.12
Underlying mechanisms of disease are being discovered
with multiple signaling pathways at work in this mouse
model of aneurysm disease.10,13 Recently, TGF-b and
AT1 receptor–dependent activation of the extracellular
signal-regulated kinases 1 and 2 in the aorta of fibrillin-1
deficient mice has been demonstrated to be involved in an-
eurysm formation. Importantly, treatment with an extracel-
lular signal-regulated kinase inhibitor leads to attenuation
of pathologic aortic growth in mouse models.13 This basic
research may lead to effective treatments for these andrdiovascular Surgery c Volume 145, Number 3S S3
TABLE 1. Etiology of thoracic aortic aneurysms
Genetically triggered diseases
Marfan syndrome
Loeys-Dietz syndrome
Bicuspid aortic valve aortopathy
Familial thoracic aortic aneurysm syndromes
Vascular Ehlers-Danlos syndrome
Turner syndrome
Degenerative diseases
Atherosclerosis
Hypertension
Inflammatory diseases
Giant cell arteritis
Nonspecific aortitis
Takayasu arteritis
Reiter syndrome
Kawasaki disease
Behcet syndrome
Mechanical
Aortic dissection and variants
Trauma
Infectious diseases
Bacterial aortitis (staphylococcus, salmonella)
Syphilis
Aspergillus
Infected thoracic endovascular aortic repair
Panel 1 Bravermanmany other aneurysm syndromes. In a nonrandomized
study of young patients with Marfan syndrome and ad-
vanced aortic root dilatation despite beta-blocker therapy,
ARB therapy led to a significant reduction in the rate of aor-
tic dilatation.12 Trials of ARB therapy in Marfan syndrome
are underway and will examine whether this therapy can
attenuate aortic root dilatation in Marfan syndrome.10 An-
cillary studies examining circulating TGF-b levels, pharma-
cogenomics, and musculoskeletal features will provide
much anticipated data in this area, potentially altering the
natural history of Marfan syndrome.10
A small, randomized trial of angiotensin-converting en-
zyme (ACE)–inhibitor therapy reported a reduction in aor-
tic root and ascending aortic growth in Marfan patients.14
ACE-inhibitor therapy also was associated with a reduction
in TGF-b, matrix metalloproteinase-2 and -3 levels, and
a decrease in aortic stiffness.14 There are data comparing
ARB with ACE inhibitors in the mouse model of Marfan
syndrome, but no such data in humans. In the fibrillin-1
deficient mouse model, ARB therapy (with losartan) was
superior to ACE-inhibitor therapy (with enalapril) in pre-
venting aortic enlargement and improving aortic architec-
ture.15 This was demonstrated to be related to prevention
of TGF-b–mediated activation of extracellular signal-
regulated kinase and allowing continued signaling through
angiotensin II type 2 (AT2) receptor.15
TGF-b activation has been recognized in affected tissue
in mouse models of disease or in aortic samples in humanS4 The Journal of Thoracic and Cardiovascular Surgestudies of other aneurysm syndromes, including those asso-
ciated with Loeys-Dietz syndrome,4 BAV,16 and possibly
others.13 The BAV Study (Beta Blockers and Angiotensin
Receptor Blockers in Bicuspid Aortic Valve Disease Aort-
opathy [BAV Study NCT01202721]) is recruiting patients
with BAV in Canada and will compare the rate of ascending
aortic growth by magnetic resonance imaging in patients
randomized to ARB therapy (telmisartan) versus beta-
blocker (atenolol) versus placebo.17 Whether therapy such
as ARB, aimed at blocking TGF-b, or novel agents affecting
other pathways will affect these aneurysm diseases is as yet
unknown.
Other pharmacologic therapies have been demonstrated
effective in animal models of thoracic aortic disease. Doxy-
cycline reduces matrix metalloproteinase activity and thus
elastin destruction and has been demonstrated to reduce
AAA in animal models.1,7 Small studies of doxycycline
demonstrated attenuation of AAA growth in human
subjects.7 In fibrillin-1–deficient mice, doxycycline pre-
vents aortic root aneurysm.18 There are beneficial effects
of statin therapy in AAA tissue and on inflammatory
markers in AAA disease, mediated by inhibition of the iso-
prenoid pathway rather than the cholesterol biosynthetic
pathway.7 Pravastatin has also demonstrated benefit in the
Marfan mouse model, attenuating aortic root aneurysm
formation.19 There are no data reporting a benefit of doxy-
cycline or statin therapy in TAA disease in humans.
LIFESTYLE MODIFICATION
The patient with a TAA should have a basic understand-
ing of the condition and should undergo routine serial
imaging surveillance of the aneurysm. The patient, family,
and physician should be educated about the risk of aortic
dissection (and rupture) as well as the symptoms of such
aortic catastrophes. The patient should be educated to
seek emergency attention if any concerning symptoms
develop.3
Because shear stresses on the aorta may play a role in
acute aortic dissection, patientswith TAA (aswell as genetic
disorders predisposing to them) are restricted from partici-
pating in most competitive athletics as well as heavy weight
lifting.3,20 Athletes with TAAs such as in Marfan syndrome,
BAV with aneurysm, and familial TAA syndromes with
a dilated aorta (>40 mm or Z-score> 2 in children) may
only participate in low static/low dynamic sports (IA, such
as golf and bowling) and should not participate in any
sports with potential for bodily collision.20
During physical activity, especially isometric activity,
blood pressure may rise markedly. In studies of body-
builders, direct arterial blood pressure measurements of
over 300 mm Hg have been reported.21 In elite strength-
trained athletes, the aortic root and ascending aorta have
larger diameters compared with controls. The longer the
period of intense weight training, the larger the aorticry c March 2013
Braverman Panel 1diameters in these athletes.22 A series of 31 acute aortic dis-
sections were reported by Hatzaras and associates23 in the
setting of weight lifting, heavy lifting, or strenuous activity.
The mean age of this group was 47 years, and 10% had
a family history of aortic disease. The vast majority
(87%) were ascending aortic dissections, and in 26 of 31
cases, the aortic diameter was available by premortem im-
aging. In 85% of these cases, the aorta was dilated with
an average diameter of 4.6 cm (range, 3-7.8 cm).23 This
highlights the importance of recognizing the patient with
underlying TAA disease and prohibiting activities associ-
ated with increased aortic stress.3,20
Pregnancy is an important consideration in the manage-
ment of women with TAA disease.1,3,24 One should
discuss birth control methods and the risks of aortic
dissection before conception in women at risk. It is
difficult to quantify the exact risk of aortic dissection for
the individual woman with TAA disease, and much of the
information is derived from series of patients with Marfan
syndrome.24 Although all women with Marfan syndrome
are considered at increased risk of aortic dissection during
pregnancy or early postpartum, the greatest threat occurs
when there is an aortic aneurysm larger than 40 mm or prior
aortic dissection.24 We25 reported data on 15 women with
acute aortic dissection during pregnancy or early postpar-
tum from the International Registry of Acute Aortic Dissec-
tion database. Most women had a recognized underlying
connective tissue disorder or aortopathy. Of the 8 type A dis-
sections, the average aortic root diameter at dissection was
53 mm (range, 41-76 mm). Importantly, the type B dissec-
tions related to pregnancy often occurred in nondilated or
only mildly dilated aortas (average size of descending aorta,
32 mm; range, 24-57 mm).25 Multidisciplinary evaluation
with maternal fetal medicine or high-risk obstetrics and
consultations with anesthesia, cardiology and cardiac sur-
gery and genetics are important in managing these patients.
IMAGING SURVEILLANCE
Once the diagnosis of TAA is established, it is imperative
that long-term imaging surveillance of the aorta at regular
intervals be performed.1,3 It is also important to consider
body size when evaluating the significance of aortic
root dimensions.1-3 When an aortic root or ascending
aortic aneurysm is present, an echocardiogram should be
performed to evaluate for the presence of a BAV, one of
the most common causes of a dilated aorta.5 One generally
recommends repeat imaging of the TAA 6 months after
initial diagnosis to ensure stability in aortic dimension.1 If
stable, then reevaluating the TAA with at least yearly
computed tomographic or magnetic resonance imaging is
recommended.
For the degenerative TAA of 3.5 to 4.4 cm, annual imag-
ing is suggested.3 For the degenerative aneurysm of 4.5 to
5.4 cm, semiannual computed tomography or magneticThe Journal of Thoracic and Caresonance imaging is suggested.3 If the aorta demonstrates
more rapid growth or is approaching the threshold for sur-
gery or endovascular repair, imaging every 3 to 6 months
is recommended.1 For genetic syndromes, the aortic dimen-
sion at which prophylactic repair is recommended is smaller
than for degenerative aneurysms and depends on the specific
condition, the rate of growth, the family history, and other
factors.1-3 After surgery or endovascular repair, long-term
imaging of the thoracic aorta by computed tomography or
magnetic resonance imaging remains important to evaluate
for any complications or subsequent aneurysm formation.CONCLUSIONS
Patients with TAA disease require multidisciplinary
management, including evaluation for an underlying ge-
netic condition and screening of family members for TAA
disease. Once the diagnosis is established, patients require
long-term imaging for progressive aneurysm enlargement
and instructions on lifestyle modifications to lessen stress
on the aorta. Although only limited data are available on
pharmacologic therapy in TAA disease, research involving
animal models has identified multiple pathways underlying
the pathogenesis of aneurysm syndromes. This research
holds great promise for translation into effective therapy
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